DNA testing, or genetic testing, comes in many types – e.g. relationships, ancestry, cancers, medical diagnosis, etc. In general, genetic testing is a type of test that can identify changes in the genes, chromosomes or proteins in your body. Genetic testing takes a sample of either blood, skin, hair, tissue or amniotic fluid. Depending on the type of test, some tests may be able to confirm or rule out if you have a genetic condition. It may also help determine your chances of developing or passing on a genetic disorder (e.g. thalassemia).

On the other hand, Pharmacogenomics examines the relationship between an individual's genetic makeup and their body’s response to medications. It investigates how genetic variations can influence the efficacy, safety, and metabolism of medications. With Pharmacogenomics, it can help healthcare professionals to personalise treatment plans, and optimise medication selection and dosage for patients. While it is not necessary to have both tests done together, what type of DNA tests you intend to do will give you different outcomes. When DNA tests are performed accurately, the test results may help to diagnose or uncover potential or the tendency to develop certain health condition(s) / disease(s). But when our PRECISE Pharmacogenomics (PGx) test is performed, it can help doctors choose the safest, most accurate and most effective drug, including dosage according to you, while minimising/preventing Adverse Drug Reactions (ADRs).

Preventive measures or treatment can be lifesaving, be it now or in the future.

Gene has many functions, one of which is to instruct the body’s cells to build protein molecules known as enzymes. One of the many functions of enzymes is to break down (metabolise) medications, which allows the medication to take effect and deliver (distribute) to the intended area.

Our PRECISE Pharmacogenomics (PGx) reports provide access to genome-wide markers coverage of close to ~100,000 ADME markers and more than 1,000 genes, covering more than 500 commonly used drugs like pain-killer, antibiotics, diabetes, heart disease-related, cancer, etc. Most genetic tests in the market does not provide such comprehensive reports and they are only allowed to be used as references. However, PRECISE Pharmacogenomics (PGx) was awarded the “First Clinical Recommended Genome-Wide Pharmacogenomics” by The Malaysia Book of Records (MBR). In other words, only healthcare professionals such as clinicians & medical doctors can refer to the PRECISE Pharmacogenomics (PGx) report and provide you with clinical recommendations, diagnosis, and personalised treatment plans alongside other clinical findings. However, this report DOES NOT replace your visit to a healthcare professional.

Click Here for more information and examples;

With an analytical accuracy and reliability of over 99%, our genome-wide platform has proven to be highly precise and dependable. The clinical recommendations in our report are accredited by the Health Science Authority (HSA) of Singapore – HSA Class A Medical Device, NQA (National Quality Assurance Limited) accredited by UKAS (United Kingdom Accreditation Service) for ISO13485 certified; while our laboratory operations strictly adhere to the standards set by CAP and ISO 15189.

For the Pharmacogenomics Report, only healthcare professionals such as doctors, medical officers, geneticists, and pharmacists are authorised.

Your report results can be located at our app, PreciseEHR, available on the iOS and Android.

For more information, you can visit https://beacondiagnostics.com.my/preciseehr/

An encrypted secured report will be sent to you

Compliance with PDPA

At Beacon Precision Diagnostics, we’re fully committed to strict adherence to the provisions of the Personal Data Protection Act 2010 (The PDPA 2010). All information is transmitted using a secure connection & stored in an encrypted & password-protected database. Access to Your DNA results requires a password, and you retain full control over How your results are utilised or shared with third parties.

We will never engage in the disclosure or sale of your information to any unidentified mystery partners. Each sample we receive is assigned A unique ID, carefully designed to exclude any patient identifiers or personal details.

By prioritising the protection of your data, we aim to provide you with peace of mind. Our unwavering commitment to privacy, confidentiality, and security ensures that your information is handled with the utmost care and diligence. You can confidently rely on us to maintain the highest level of data protection throughout our operations.

ATCC, known as Advancing Tomorrow's Cure Community, is a community established by Beacon Hospital to study how Asian genetics react to current medicines.

Your deidentified sample will be stored indefinitely as anonymous specimens for the option of being able to update your report at the minimal cost after the first FOC update with joining the ATCC, as well as for research purposes. Only an identification specimen number will be used, ensuring the anonymity and privacy of your data.

As for the possibility of research direction changes leading to activities related to cloning, Malaysia does not support human cloning therefore we will not be embarking on this area of research. Pharmacogenomics primarily focuses on understanding how an individual's genetic makeup influences their response to drugs, optimising drug therapy based on genetic factors, and advancing personalized medicine. While research directions can evolve over time, the core focus of pharmacogenomics remains centered on drug response and genetic variability rather than cloning or genetic manipulation for other purposes.